Yourlocation: Home > News > Neurological outcome in cerebrotendinous xanthomatosis treated with chenodeoxycholic acid
Objective: To present the long-term neurological outcome of Jewish Israeli patients with cerebrotendinous xanthomatosis (CTX) after several years of chenodeoxycholic acid (CDCA) treatment.
Methods: A cross sectional observational study of all patients with a diagnosis of CTX followed in a referral outpatient clinic during the years 2003–2012.Results: Eighteen patients (10 men) from 11 families were enrolled. Sixteen patients were included in the analysis (2 patients had low compliance for treatment). The mean ± SD age at last evaluation was 35.0 ± 9.2 years (range, 16–45 years). After their diagnosis, at age 22.6 ± 10.8 years, all patients were treated with CDCA. Patients who started treatment after the age of 25 years had worse outcome and were significantly more limited in ambulation (P = 0.004) and more cognitively impaired (P = 0.047). Five patients who started treatment after 25 years of age continued to deteriorate despite Chenodeoxycholic Acid treatment.
Conclusions: Beginning Chenodeoxycholic Acid treatment as early as possible is crucial to preventing neurological damage and deterioration in CTX. After significant neurological pathology is established, the effect of treatment is limited and deterioration may continue.
Establish THPLC-ELSD determination of bear bile powder extract of ursodeoxycholic acid and chenodeoxycholic acid, C18 column with 0.05% trifluoroacetic acid - acetonitrile gradient, evaporative light scattering detector drift tube temperature of 95 ℃. ursodeoxycholic acid and chenodeoxycholic acid respectively 2.51 ~ 12.54μg and 0.40 ~ 2.02μg good linear relationship, the recovery rate was 98.8% and 99.8%, RSD 1.4% and 2.1%.

Address:A3 Building, Dongli Aviation Business District,No.8,Pingying Road, Dongli District, Tianjin, P.R.China, 300300 Tel:+86-022-58602231 Fax:+86-022-58602232
Copyright © Tianjin NWS Biotechnology and Medicine Co. Ltd.